계명대학교 의학도서관 Repository

A randomized study of cisplatin and 5‑FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

Metadata Downloads
Author(s)
정우진황재석
Alternative Author(s)
Chung, Woo JinHwang, Jae Seok
Publication Year
2015
Abstract
Purpose : This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients.
Methods : Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m2 on day 1, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints.
Results : Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95 % CI 2.580–16.064)] was independently associated with OS. Age (≥60 years) and serum AFP level (≥200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95 % CI 1.543–15.850), P = 0.048, HR 2.677 (95 % CI 1.010–7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups.
Conclusions : Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC.
Keywords : Hepatocellular carcinoma – Hepatic arterial infusion chemotherapy – 5-Fluorouracil – Cisplatin
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Cancer Chemotherapy and Pharmacology, Vol.75(4) : 739-746, 2015
Type
Article
ISSN
0344-5704
DOI
10.1007/s00280-015-2692-0
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35291
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.